Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Theratechnologies Inc. (TH.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
3.6300+0.0300 (+0.83%)
At close: 03:59PM EST
Advertisement
Sign in to post a message.
  • C
    Charlie
    nice chart developing ,will be buying more this week if stock stays under $3.00
    Bullish
  • A
    Anonymous
    What will be THERA’s first PR of the year?
  • z
    zaigham
    What is going on?
  • v
    victor
    Insiders are playing tricks again!
  • H
    H
    Stuck in a rut!
  • C
    Charlie
    stock up and volume buyside up,higher end of year larger
    Bullish
  • H
    H
    Under 2.00$ this year is a possibility. Small cap biotechs are left for dead.
  • C
    Charlie
    volume and upside buying, maybe $5 before end of year
    Bullish
  • K
    Kev
    charlie where is your 6$ ?
  • H
    H
    Would not be surprised to see another 20% leg down in THTX. It's struggling and company has gone silent!
  • v
    victor
    What kind of the game they are playing now? It seems to be someone in the market is controlling the trend of this stock.
  • Y
    Yahoo Finance Insights
    TH.TO is up 6.65% to 4.17
  • C
    Charlie
    $5.50 very very soon, just keep watching the volume pick up
    Bullish
  • A
    Anonymous
    If the data is good, then this is their target date: ASCO Abstract Submission Deadline: February 15, 2022, oral presentation as a target.
  • A
    Anonymous
    The coronavirus can infect body fat, scientists said. The research may explain why people who are overweight or obese face greater risk of severe illness and death from Covid. EGRIFTA to the rescue
  • Y
    Yahoo Finance Insights
    TH.TO is up 5.13% to 4.30
  • d
    david
    Oncology:
    As per new dose escalation slide they dosed first patient with 30mg/m2 second patient 2x30mg/m2=60mg/m2 third patient 2x60mg/m2=120mg/m2 forth patient 1.67x120mg/m2=200mg/m2 fifths patient 200mg/m2x1.5=300mg/m2 and last single and sixth patient 300mg/m2x1.4=420mg/m2, it seems they have started dosing group of 3 patients at 420mg/m2 if no DLT planning to increase the dosage by factor of 1.33(420mg/m2x1.33)560mg/m2 on next group of 3 if DLT they dose a group of 6 if less than 1or more with DLT they increase the dosage by factor of 1.33 again in next group of 6 patients until 1 or more patient shows DLT. He confirmed even at twice the level of Docetaxel their intracellular concentration of anti-cancer agent could be multiples of Docetaxel alone theoretically up to 8 time more.
    It looks like the amount of Docetaxel released in blood stream in humans is similar to animals based are incoming data which they haven’t published but are monitoring. Paul mentioned they will be starting the combination therapy (TH19 series+ immunotherapy) possibilities in clinic. Their peptide can potentially conjugate to SN-38 a very potent cytotoxic agent and small interfering RNA (molecule which can regulate and effect the expression of genes) in order to silence the protein responsible for cancer cells growth.
    NASH:
    They are having conversations with few potential partners failing that they want to fund the trial in a responsible manner without effecting the investors negatively.
    They have a commercial business which can be used as a collateral in order to raise funds. Also they will be finding the trial in in installments ”chops of payments” so there is no need to raise huge amount of funds initially.
    Legacy drugs:
    They are optimistic on Tesamorelin as it seems both passed sales and incoming prescription are rising and Trogarzo (long lasting drug) which “seems to be more relevant now” will be launched in multiple European countries once the pricing is confirmed
  • A
    Anonymous
    Too late for GSK. GSK passed and went with Arrow for NASH. What's this CEO planning??
  • C
    Charlie
    Credit Suisse will have buy rec out soon, let alone the new buyers from the conference, could be$5 this week
    Bullish
  • C
    Charlie
    over $6 after conference this week
    Bullish
Advertisement
Advertisement